source · application/json
source_22cb62a8cbb7440e
sha256 085b2c4e5c93ea93aea966366f17749076139ee56f06b31590e018e407039425
by researka:v2 · 2026-06-19 00:45:24.671473+04:00
{"publication_id": "060fa963-9582-4658-ad87-91a057301d4f", "traces": [{"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "This paper synthesizes evidence on semaglutide adverse safety across 15 accepted source papers and 1436 high-confidence extracted claims.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The evidence profile contains 2 direct clinical sources, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 27 cross-study disagreements across the evidence base.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Positive study-level signals are summarized in the safety and comorbidity, cardiometabolic outcome classes, null signals in the dosing and pharmacokinetics, safety and comorbidity outcome classes, and negative signals in the safety and comorbidity outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The conclusion is that semaglutide adverse safety remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "This synthesis evaluates evidence on semaglutide adverse safety across 15 included source papers and 1436 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The corpus contains 2 direct clinical sources, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The thesis is: Across 15 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: safety comorbidity, cardiometabolic. Negative signals appear in: safety comorbidity. Null findings dominate: dosing pharmacokinetics, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.", "claim_id": "claim_12"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.", "claim_id": "claim_13"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The background evidence for semaglutide adverse safety is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Hamarsheh 2026, Kushner 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "claim_id": "claim_14"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "claim_id": "claim_15"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Across the retained sources, positive signals cluster around the safety and comorbidity, cardiometabolic outcome classes; null signals around the dosing and pharmacokinetics, safety and comorbidity outcome classes; and negative or adverse signals around the safety and comorbidity outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.", "claim_id": "claim_16"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "claim_id": "claim_17"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.", "claim_id": "claim_18"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.", "claim_id": "claim_19"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).", "claim_id": "claim_20"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, safety, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_21"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_22"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.", "claim_id": "claim_23"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |", "claim_id": "claim_24"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "| Contextual Adjacent Evidence | n=2; claims=582 | unclear signal in 1/2 sources | 1 direct; 1 review | limited corpus depth in this outcome class |", "claim_id": "claim_25"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Contextual Adjacent Evidence: n=2; claims=582; mixed signal in 1/2 sources | directness: 1 direct; 1 review; main limitation: directionally heterogeneous.", "claim_id": "claim_26"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Quantitative findings diverge in direction across the three sources. Strathe 2026 reaches P < 0.01 in its adolescent dose-extrapolation model, with an effect direction labeled mixed. the evidence synthesis carries the full per-study endpoint p-value matrix so the reader can inspect each study × endpoint tuple directly.", "claim_id": "claim_27"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "By contrast, the unclear effect direction in McGowan 2025 reflects the review's aggregation of heterogeneous RCTs, where individual trial improvements on lipid profile, blood pressure, HbA1c, and fasting plasma glucose are pooled against null or conflicting comparators. The mechanistic substrate underlying this functional finding — incretin-driven reductions in glucagon, slowing of gastric emptying, and centrally mediated satiety — is consistent across the three sources even where statistical directionality diverges.", "claim_id": "claim_28"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Within the corpus, the principal tension is between the single positive real-world signal from Buenaventura-Collazos 2024 (P < 0.001, P = 0.008) and the mixed/unclear pooled directionality in McGowan 2025 and Strathe 2026. The disagreement is best read as a difference between a single-cohort effectiveness study and aggregated efficacy reviews plus a pharmacokinetic extrapolation; it is not a contradiction of underlying biology but a disagreement about how to weight direct clinical observation versus pooled indirect evidence. The cardiometabolic case for semaglutide therefore rests on a positive observational anchor (Buenaventura-Collazos 2024) with supportive but directionally ambiguous modeling and review evidence (Strathe 2026; McGowan 2025).", "claim_id": "claim_29"}, {"candidate_sources": [{"doi": "10.1002/edm2.70248", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials", "url": "https://doi.org/10.1002/edm2.70248"}, {"doi": "10.1007/s00125-024-06144-1", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "url": "https://doi.org/10.1007/s00125-024-06144-1"}, {"doi": "10.1038/s41591-025-03978-z", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults", "url": "https://doi.org/10.1038/s41591-025-03978-z"}, {"doi": "10.1186/s12902-024-01658-6", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)", "url": "https://doi.org/10.1186/s12902-024-01658-6"}, {"doi": "10.1111/dom.70678", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach", "url": "https://doi.org/10.1111/dom.70678"}], "claim": "Dosing and pharmacokinetic characterization of semaglutide in non-diabetic, non-obesity populations remains protocol-stage rather than completed-trial evidence. Kimura 2025 contributes the principal design in this outcome class as a randomised, double-blind, placebo-controlled protocol evaluating oral semaglutide tablets in patients with Parkinson's disease at Hoehn & Yahr stages 1-2.5 across eight sites in Japan, with the explicit remit of establishing the disease-modifying effect, safety, and optimal dose (MOST-ABLE study). The protocol framework embeds both efficacy and safety endpoints, and is positioned to generate the dose-finding signal that currently is absent from the curated corpus.", "claim_id": "claim_30"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "060fa963-9582-4658-ad87-91a057301d4f",
"researka_submission_id": "807814a9-fc08-449b-8a72-18e47e815d0d",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/060fa963-9582-4658-ad87-91a057301d4f/sidecars/citation_traces.json"
}